{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:41:29Z","timestamp":1790232089054,"version":"4.1.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,2,1]]},"DOI":"10.1097\/qai.0b013e31815ee282","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T06:01:31Z","timestamp":1236232891000},"page":"212-220","source":"Crossref","is-referenced-by-count":43,"title":["Determinants of HIV Progression and Assessment of the Optimal Time to Initiate Highly Active Antiretroviral Therapy"],"prefix":"10.1097","volume":"47","author":[{"given":"\u00c1ngeles","family":"Ja\u00e9n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M","family":"Mir\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Tural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Montoliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melcior","family":"Riera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferran","family":"Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lluis","family":"Force","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Sued","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Vilar\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angels","family":"Masabeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Alt\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonaventura","family":"Clotet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Podzamczer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Murillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M","family":"Gatell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Casabona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210131","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"R2-11-20210131","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1097\/00002030-200111230-00006","article-title":"HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy.","volume":"15","author":"Sterling","year":"2001","journal-title":"AIDS"},{"key":"R3-11-20210131","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/aje\/kwg036","article-title":"When to initiate highly active antiretroviral therapy: a cohort approach.","volume":"157","author":"Ahdieh-Grant","year":"2003","journal-title":"Am J Epidemiol"},{"key":"R4-11-20210131","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1001\/jama.286.20.2568","article-title":"Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.","volume":"286","author":"Hogg","year":"2001","journal-title":"JAMA"},{"key":"R5-11-20210131","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1097\/00002030-200208160-00020","article-title":"Survival rates after the initiation of antiretroviral therapy stratified by CD4 cell counts in two cohorts in Canada and the United States.","volume":"16","author":"Chan","year":"2002","journal-title":"AIDS"},{"key":"R6-11-20210131","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1086\/377606","article-title":"When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts 350 cells\/L.","volume":"37","author":"Kaplan","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R7-11-20210131","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(02)09411-4","article-title":"Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.","volume":"360","author":"Egger","year":"2002","journal-title":"Lancet"},{"key":"R8-11-20210131","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/aje\/155.8.760","article-title":"Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.","volume":"155","author":"Jacobson","year":"2002","journal-title":"Am J Epidemiol"},{"key":"R9-11-20210131","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-138-8-200304150-00007","article-title":"Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata.","volume":"138","author":"Palella","year":"2003","journal-title":"Ann Intern Med"},{"key":"R10-11-20210131","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1097\/00002030-200212060-00011","article-title":"Virologic and immunologic values allowing safe deferral of antiretroviral therapy.","volume":"16","author":"Phair","year":"2002","journal-title":"AIDS"},{"key":"R11-11-20210131","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1086\/379741","article-title":"Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study.","volume":"188","author":"Sterling","year":"2003","journal-title":"J Infect Dis"},{"key":"R12-11-20210131","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/00002030-200207050-00009","article-title":"Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count 350 10(6)\/l.","volume":"16","author":"Opravil","year":"2002","journal-title":"AIDS"},{"key":"R13-11-20210131","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1002\/sim.1579","article-title":"Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies.","volume":"23","author":"Cole","year":"2004","journal-title":"Stat Med"},{"key":"R14-11-20210131","first-page":"525","article-title":"Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project.","volume":"124","author":"Jaen","year":"2005","journal-title":"Med Clin (Barc)"},{"key":"R15-11-20210131","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1157\/13069520","article-title":"Spanish GESIDA\/national AIDS plan recommendations for antiretroviral therapy in HIV-infected adults (October 2004).","volume":"22","author":"Iribarren","year":"2004","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"RR-17","key":"R17-11-20210131","first-page":"1","article-title":"1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.","volume":"41","year":"1992","journal-title":"MMWR Recomm Rep"},{"key":"R19-11-20210131","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1468-1293.2006.00397.x","article-title":"CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells\/L.","volume":"7","author":"Moore","year":"2006","journal-title":"HIV Med"},{"key":"R20-11-20210131","doi-asserted-by":"crossref","first-page":"946","DOI":"10.7326\/0003-4819-126-12-199706150-00003","article-title":"Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.","volume":"126","author":"Mellors","year":"1997","journal-title":"Ann Intern Med"},{"key":"R21-11-20210131","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00002030-200401020-00006","article-title":"Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era.","volume":"18","author":"Phillips","year":"2004","journal-title":"AIDS"},{"key":"R22-11-20210131","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/00126334-200307010-00013","article-title":"Time-updated CD4+ T-lymphocyte count and HIV RNA as major markers of disease progression in naive HIV-1-infected patients treated with a highly active antiretroviral therapy: the Aquitaine Cohort, 1996-2001.","volume":"33","author":"Thiebaut","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R23-11-20210131","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/01.aids.0000163934.22273.06","article-title":"Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy.","volume":"19","author":"Nicastri","year":"2005","journal-title":"AIDS"},{"key":"R24-11-20210131","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1136\/jech.2003.017475","article-title":"Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001.","volume":"58","author":"Garcia de la Hera","year":"2004","journal-title":"J Epidemiol Community Health"},{"key":"R25-11-20210131","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1089\/08892220152644160","article-title":"Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients.","volume":"17","author":"Martin-Carbonero","year":"2001","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R26-11-20210131","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1086\/321909","article-title":"Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis.","volume":"33","author":"Graham","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R27-11-20210131","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1086\/345953","article-title":"Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy.","volume":"36","author":"Tedaldi","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R28-11-20210131","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1086\/432762","article-title":"Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.","volume":"192","author":"Rockstroh","year":"2005","journal-title":"J Infect Dis"},{"key":"R29-11-20210131","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1001\/archinte.162.18.2125","article-title":"Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects.","volume":"162","author":"De Luca","year":"2002","journal-title":"Arch Intern Med"},{"key":"R30-11-20210131","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/S0140-6736(00)03232-3","article-title":"Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study.","volume":"356","author":"Greub","year":"2000","journal-title":"Lancet"},{"key":"R31-11-20210131","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1086\/426513","article-title":"Hemophilia Growth and Development Study. Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease.","volume":"191","author":"Yoo","year":"2005","journal-title":"J Infect Dis"},{"key":"R32-11-20210131","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1097\/00002030-200411190-00012","article-title":"The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy.","volume":"18","author":"Dorrucci","year":"2004","journal-title":"AIDS"},{"key":"R33-11-20210131","doi-asserted-by":"crossref","first-page":"87","DOI":"10.7326\/0003-4819-146-2-200701160-00003","article-title":"Survival of persons with and without HIV infection in Denmark, 1995-2005.","volume":"146","author":"Lohse","year":"2007","journal-title":"Ann Intern Med"},{"key":"R34-11-20210131","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(06)69152-6","article-title":"HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis.","volume":"368","year":"2006","journal-title":"Lancet"},{"key":"R35-11-20210131","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1001\/jama.280.17.1497","article-title":"Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.","volume":"280","author":"Detels","year":"1998","journal-title":"JAMA"},{"key":"R36-11-20210131","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/aje\/154.7.675","article-title":"Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts.","volume":"154","author":"Tarwater","year":"2001","journal-title":"Am J Epidemiol"},{"key":"R37-11-20210131","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/aje\/kwg206","article-title":"Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models.","volume":"158","author":"Cole","year":"2003","journal-title":"Am J Epidemiol"},{"key":"R38-11-20210131","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0140-6736(05)67022-5","article-title":"Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study.","volume":"366","author":"Sterne","year":"2005","journal-title":"Lancet"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00003226-200807000-00026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T07:21:21Z","timestamp":1618039281000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-200802010-00011"}},"subtitle":["PISCIS Cohort (Spain)"],"short-title":[],"issued":{"date-parts":[[2008,2,1]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e31815ee282","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2,1]]}}}